AVM Biotechnology, a clinical-stage company, advancing AVM0703 for expeditious FDA approval in patients with relapsed/refractory Non-Hodgkin’s Lymphoma/Leukemia. AVM0703 rapidly induces, expands, and mobilizes endogenous bispecific γδ TCR+ invariant TCR+ NKT-like cells by a glucocorticoid-receptor-independent mechanism and potentiates chemotherapy and CAR-T response in pre-clinical models. Durable clinical responses achieved with strong safety profile. Ph 2/3 actively enrolling. Seeking additional trial sites & strategic partners for commercial launch in 2024.